Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × OTHER_GOV × VAP-cyclo protocol × Clear all

Phase

Status

Sponsor Class

OTHER 3 NETWORK 2 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell, Peripheral 1

Interventions

Capecitabine 24 Gemcitabine 21 Cisplatin 21 tislelizumab 20 apatinib 20 Oxaliplatin 19 Paclitaxel 18 Irinotecan 17 Carboplatin 16 Docetaxel 15 Bevacizumab 13 Fluorouracil 12 Drug Therapy 12 pembrolizumab 10 camrelizumab 10 Cyclophosphamide 10 Radiation 9 Vinorelbine 8 S 1 (combination) 8 Rituximab 7 Erlotinib Hydrochloride 7 Cetuximab 7 Leucovorin 6 Gefitinib 6 Albumin-Bound Paclitaxel 6 toripalimab 5 pyrotinib 5 fludarabine 5 Radiotherapy 5 Nivolumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05963347 2023-09-01

Go-CHOP as the Frontline Therapy for PTCL

Henan Cancer Hospital

Phase 2 Recruiting

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon ⚡